European Union - English - EMA (European Medicines Agency)

vanda pharmaceuticals ltd - iloperidone - schizophrenia - psycholeptics - treatment of schizophrenia

European Union - English - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - avandamet is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - rosiglitazone maleate (unii: kx2339dp44) (rosiglitazone - unii:05v02f2kdg), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - rosiglitazone 2 mg - after consultation with a healthcare professional who has considered and advised the patient of the risks and benefits of rosiglitazone, avandamet® is indicated as an adjunct to diet and exercise to improve glycemic control when treatment with both rosiglitazone and metformin is appropriate in adults with type 2 diabetes mellitus who either are: - already taking rosiglitazone, or - not already taking rosiglitazone and unable to achieve glycemic control on other diabetes medications and, in consultation with their healthcare provider, have decided not to take pioglitazone (actos® ) or pioglitazone-containing products (actoplus met® , actoplus met xr® , duetact® ) for medical reasons. - due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. therefore, avandamet should not be used in patients with type 1 diabetes. - coadministration of avandamet with insulin is not recommended [see warnings and precautions (5.2, 5.3)] . - initiation in patients with established new

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - metformin hydrochloride,rosiglitazone maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - metformin hydrochloride,rosiglitazone maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - metformin hydrochloride,rosiglitazone maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - metformin hydrochloride,rosiglitazone maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - rosiglitazone maleate; metformin hydrochloride -

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - metformin hydrochloride 1000 mg; rosiglitazone as maleate 4 mg - tablets - metformin and rosiglitazone - avandamet is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus : as dual combination therapy in patients who are already treated with combination rosiglitazone and metformin or who are not adequately controlled on metformin alone or in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - glimepiride - tablet, film coated - 1mg